Gipuzkoa
Campus
![Foto de Gipuzkoa](/img/uploaded/FCB09D7335FCA2A3AE8EE86EE65B5B3A.jpg)
![Foto de Eli Lilly and Company](/img/noimage_org.png)
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadoras/es de Eli Lilly and Company (6)
2023
-
Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study
Rheumatology and Therapy, Vol. 10, Núm. 5, pp. 1319-1333
2022
-
Correction to: Real-world Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: Results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study) (Rheumatology and Therapy, (2022), 9, 2, (589-608), 10.1007/s40744-021-00423-8)
Rheumatology and Therapy
-
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
npj Parkinson's Disease, Vol. 8, Núm. 1
-
Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)
Rheumatology and Therapy, Vol. 9, Núm. 2, pp. 589-608
2019
-
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)
Parkinsonism and Related Disorders, Vol. 62, pp. 201-209
2018
-
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
Annals of Clinical and Translational Neurology, Vol. 5, Núm. 12, pp. 1460-1477